Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Surufatinib

From Wikipedia, the free encyclopedia
Chemical compound

Pharmaceutical compound
Surufatinib
Clinical data
Trade namesSulanda
Other namesSulfatinib; HMPL-012
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • N-[2-(Dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1H-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide
CAS Number
PubChemCID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC24H28N6O3S
Molar mass480.59 g·mol−1
3D model (JSmol)
  • CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C
  • InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29)
  • Key:TTZSNFLLYPYKIL-UHFFFAOYSA-N

Surufatinib (trade nameSulanda) is pharmaceutical drug for the treatment of cancer. In China, it is approved for late-stage, well-differentiated, extrapancreaticneuroendocrine tumors.[1]

It is also under investigation for the treatment of other types ofsolid tumors.[2][3]

Surufatinib targetsfibroblast growth factor receptor 1 (FGFR1).[4]

References

[edit]
  1. ^Syed YY (April 2021). "Surufatinib: First Approval".Drugs.81 (6):727–732.doi:10.1007/s40265-021-01489-y.PMID 33788183.
  2. ^Liao S, Li J, Gao S, Han Y, Han X, Wu Y, et al. (2023)."Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1-3, suppresses osteosarcoma proliferation and invasionvia dual role in tumor cells and tumor microenvironment".Frontiers in Oncology.13: 1158857.doi:10.3389/fonc.2023.1158857.PMC 10286821.PMID 37361567.
  3. ^Xu JM, Wang Y, Chen YL, Jia R, Shen L, Wang J, et al. (2014). "First-in-human (FIH) phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors".Journal of Clinical Oncology.32 (15_suppl): 2615.doi:10.1200/jco.2014.32.15_suppl.2615.
  4. ^Lin Q, Dai S, Qu L, Lin H, Guo M, Wei H, et al. (January 2024)."Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R".Communications Chemistry.7 (1): 3.doi:10.1038/s42004-023-01084-0.PMC 10764862.PMID 38172256.
CImonoclonal antibodies ("-mab")
Receptor tyrosine kinase
Others for solid tumors
Leukemia/lymphoma
Other
Tyrosine kinase inhibitors ("-nib")
Receptor tyrosine kinase
Non-receptor
Other


Stub icon

Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Surufatinib&oldid=1232712386"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp